Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.01 EUR
Change Today +0.037 / 3.80%
Volume 0.0
4LS On Other Exchanges
As of 1:01 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

athersys inc (4LS) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/23/15 - €3.13
52 Week Low
04/17/15 - €0.74
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ATHERSYS INC (4LS)

Related News

No related news articles were found.

athersys inc (4LS) Related Businessweek News

No Related Businessweek News Found

athersys inc (4LS) Details

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has completed Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic stem cell transplant/graft-versus-host disease. It is also developing MultiStem cell therapy for the treatment of acute respiratory distress syndrome. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. In addition, the company is involved in identifying and developing small molecule compounds with potential applications in indications, including obesity; related metabolic conditions, such as diabetes; and neurological indications consisting of schizophrenia. It has license agreement with Chugai Pharmaceutical Co., Ltd. to develop MultiStem cell therapy for ischemic stroke in Japan, as well as collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; and collaboration with Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets produced compound screening and development. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

57 Employees
Last Reported Date: 03/12/15
Founded in 1995

athersys inc (4LS) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $599.8K
President and Chief Operating Officer
Total Annual Compensation: $464.5K
Co-Founder, Chief Scientific Officer, Executi...
Total Annual Compensation: $462.0K
Vice President of Finance
Total Annual Compensation: $283.3K
Compensation as of Fiscal Year 2014.

athersys inc (4LS) Key Developments

Athersys, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter Ended September 30, 2015

Athersys, Inc. reported unaudited consolidated earnings results for the third quarter ended September 30, 2015. For the quarter, the company reported total revenues of $396,000 compared to $293,000 a year ago. Loss from operations was $6,700,000 compared to $7,268,000 a year ago. Loss before taxes was $6,524,000 compared to $4,720,000 a year ago. Net loss and comprehensive loss was $6,497,000 or $0.08 per diluted share which included non-cash income of $0.3 million from the warrant valuation and non-cash expense of $0.7 million from stock-based compensation compared to $4,719,000 or $0.08 per diluted share a year ago. Net cash used in operating activities was $3,681,000 compared to $6,248,000 a year ago. Purchases of equipment were $26,000 compared to $79,000 a year ago.

Athersys, Inc. and Chugai Pharmaceutical Co., Ltd. End License Agreement

Athersys, Inc. announced that Athersys and Chugai Pharmaceutical Co. Ltd. (Chugai) have ended the license agreement between them for the exclusive development and commercialization of MultiStem cell therapy for ischemic stroke in Japan. The parties were unable to reach an agreement on the modification of the financial terms of the agreement and on development strategy in Japan, in light of the results from the Phase 2 clinical study. All rights will revert to Athersys, and Athersys will retain the $10 million license fee paid by Chugai. Additionally, Athersys announced that it has entered into a letter of intent with a Japanese company, accompanied by a good faith payment, to collaborate on the development and commercialization of MultiStem cell therapy for several indications in Japan, including ischemic stroke.

Athersys, Inc. to Report Q3, 2015 Results on Nov 05, 2015

Athersys, Inc. announced that they will report Q3, 2015 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4LS:GR €1.01 EUR +0.037

4LS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $4.25 USD 0.00
Capricor Therapeutics Inc $4.34 USD -0.26
Cytori Therapeutics Inc $0.37 USD -0.0006
Pluristem Therapeutics Inc $1.39 USD +0.01
StemCells Inc $0.54 USD +0.0021
View Industry Companies

Industry Analysis


Industry Average

Valuation 4LS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 55.3x
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ATHERSYS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at